52MEDIUM

CBL

CTRLBIONIC FPO [CBL]
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. The company also provides the NeuroStrip, a wearable, miniaturized electromyography device; NeuroNode, a wireless, wearable sensor that allows users to access technology through bioelectric signals and spatial movements; and Cosmos Connect, a small portable control device that turns a single NeuroNode sensor into multiple outputs. In addition, it offers mounting systems under the Rehadapt brand, including wheelchair mounts, floor stands, and table stands; switch systems comprising proximity, press, and finger switches; and the autonomous wheelchair module under the DROVE brand. The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020. Control Bionics Limited was incorporated in 2005 and is headquartered in Cremorne, Australia.
Healthcare · ASX Small Cap
$0.0520 -10.3%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical45
Catalyst50
Sentiment50
Fundamental55
Momentum75
Risk Gate47
Get alerts when CBL's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track CBL — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • Sitting near support — this level has held before and could attract buyers again
  • Took a hit — down 13.3% over the last 5 days
  • Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
  • Trading above the 200-day average — the long-term trend is on your side
  • Low cash runway (3 quarters) - dilution risk
  • Low P/S ratio (3.5x)
  • Small-cap ($20-100M)
  • CANSLIM S: Tight float (34%)
  • CANSLIM I: Institutional ownership (18%)
  • Sentiment is mixed — no strong consensus either way
  • Strong long-term momentum — up 100% over the past year (excluding last month)
  • The bigger volume days are the up days — volume-weighted momentum is positive (0.66%/day)
  • RBA hiking (-3pts)

Risk Signals

  • MACD crossed bearish — momentum is fading
  • Trading below both moving averages — the trend is working against this one
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Deeply negative margins (-107%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about CBL
"What's driving CBL's score?" "How does CBL compare to peers?" "Key risks for CBL?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE First U.S. Letter of Intent for iOS Speech Device Program
NONE German Statutory Reimbursement Listing for NeuroNode
NONE Change of Director's Interest Notice - Rix

Recent ASX Announcements

2026-03-25 First U.S. Letter of Intent for iOS Speech Device Program
2026-03-03 German Statutory Reimbursement Listing for NeuroNode PRICE SENSITIVE
2026-03-02 Change of Director's Interest Notice - Rix
2026-02-25 Investor call presentation
2026-02-25 Joint venture with NextLevel Assistive Technology PRICE SENSITIVE

Key Metrics

$21.4M
Market Cap
198K
Avg Volume
1.4x
Vol Ratio
$0.03 — $0.09
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-91.6%
ROE
-107.0%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandpassFloat: 34%
LLeader vs LaggardlaggardRS: -3
IInstitutional SponsorshippassInst: 18%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #20 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:CBL vs ATXCBL vs PNVCBL vs IMM
Scout Pro — Deeper Analysis for CBL
Try Pro free for 30 days
Share this analysis

Track CBL and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required